A transcription factor is a protein that regulates the transcription of genetic information from DNA to RNA, playing a pivotal role in the regulation of gene expression.

AskBio, part of the Bayer Group, commences a Phase II clinical study, GenePHIT, targeting the treatment of Congestive Heart Failure (CHF).

In the latest Synapse update, we've added a feature that displays bull's-eye charts for drug analysis and competitive landscape details (targets, indications, drug types).

Elicio Therapeutics, Inc. announced the first participant treated in a Phase 2 trial of ELI-002 7P, an adjuvant monotherapy for KRAS-mutant pancreatic ductal adenocarcinoma.

In biology, a terminator is a sequence of nucleotides that marks the end of a gene or operon during the transcription process.

Aclaris Therapeutics, working on immune-related treatments, shared initial Phase 2b results. They tested ATI-1777, a new topical JAK 1/3 inhibitor, on atopic dermatitis patients.

In clinical trials, a placebo is an inactive substance or other intervention that looks the same and tastes the same as the active drug being tested.

EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.

In clinical trials, a sham is a procedure or device that looks the same and feels the same as an active treatment being tested but doesn’t actually do anything.

Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.

Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).